Modulation of TDM-induced granuloma pathology by human lactoferrin: a persistent effect in mice.
Granuloma
Immunopathology
Inflammation
Lactoferrin
Trehalose 6,6′-dimycolate
Tuberculosis
Journal
Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine
ISSN: 1572-8773
Titre abrégé: Biometals
Pays: Netherlands
ID NLM: 9208478
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
03
06
2022
accepted:
08
08
2022
medline:
15
5
2023
pubmed:
18
8
2022
entrez:
17
8
2022
Statut:
ppublish
Résumé
Lactoferrin (LTF), an iron binding protein, is known to exhibit immune modulatory effects on pulmonary pathology during insult-induced models of primary Mycobacterium tuberculosis (Mtb) infection. The effects of LTF correlate with modulation of the immune related development of the pathology, and altering of the histological nature of the physically compact and dense lung granuloma in mice. Specifically, a recombinant human version of LTF limits immediate progression of granulomatous severity following administration of the Mtb cell wall mycolic acid, trehalose 6,6'-dimycolate (TDM), in part through reduced pro-inflammatory responses known to control these events. This current study investigates a limited course of LTF to modulate not only initiation, but also maintenance and resolution of pathology post development of the granulomatous response in mice. Comparison is made to a fusion of LTF with the Fc domain of IgG2 (FcLTF), which is known to extend LTF half-life in circulation. TDM induced granulomas were examined at extended times post insult (day 7 and 14). Both LTF and the novel FcLTF exerted sustained effects on lung granuloma pathology. Reduction of pulmonary pro-inflammatory cytokines TNF-α and IL-1β occurred, correlating with reduced pathology. Increase in IL-6, known to regulate granuloma maintenance, was also seen with the LTFs. The FcLTF demonstrated greater impact than the recombinant LTF, and was superior in limiting damage to pulmonary tissues while limiting residual inflammatory cytokine production.
Identifiants
pubmed: 35976499
doi: 10.1007/s10534-022-00434-0
pii: 10.1007/s10534-022-00434-0
doi:
Substances chimiques
Cord Factors
0
Lactoferrin
EC 3.4.21.-
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
603-615Subventions
Organisme : NIAID NIH HHS
ID : R42 AI117990
Pays : United States
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Abdalla AE, Lambert N, Duan X, Xie J (2016) Interleukin-10 family and tuberculosis: an old story renewed. Int J Biol Sci 12(6):710–717. https://doi.org/10.7150/ijbs.13881
doi: 10.7150/ijbs.13881
pubmed: 27194948
pmcid: 4870714
Actor JK (2021) Recombinant human lactoferrin reduces inflammation and increases fluoroquinolone penetration to granulomas during mycobacterial infection. In The 15th International Conference on Lactoferrin Structure, Function and Applications. Beijing, China.
Actor JK, Hwang SA, Kruzel ML (2009) Lactoferrin as a natural immune modulator. Curr Pharm Des 15(17):1956–1973. https://doi.org/10.2174/138161209788453202
doi: 10.2174/138161209788453202
pubmed: 19519436
pmcid: 2915836
Actor JK, Hwang SA, Olsen M, Zimecki M, Hunter RL Jr, Kruzel ML (2002) Lactoferrin immunomodulation of DTH response in mice. Int Immunopharmacol 2(4):475–486. https://doi.org/10.1016/s1567-5769(01)00189-8
doi: 10.1016/s1567-5769(01)00189-8
pubmed: 11962727
Beck A, Reichert JM (2011) Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. Mabs 3(5):415–416. https://doi.org/10.4161/mabs.3.5.17334
doi: 10.4161/mabs.3.5.17334
pubmed: 21785279
pmcid: 3225844
Bowdish DM, Sakamoto K, Kim MJ, Kroos M, Mukhopadhyay S, Leifer CA et al (2009) MARCO, TLR2, and CD14 are required for macrophage cytokine responses to mycobacterial trehalose dimycolate and mycobacterium tuberculosis. PLoS Pathog 5(6):e1000474. https://doi.org/10.1371/journal.ppat.1000474
doi: 10.1371/journal.ppat.1000474
pubmed: 19521507
pmcid: 2688075
Bukowska-Osko I, Sulejczak D, Kaczynska K, Kleczkowska P, Kramkowski K, Popiel M et al (2022) Lactoferrin as a human genome “Guardian”-an overall point of view. Int J Mol Sci 23(9):5248. https://doi.org/10.3390/ijms23095248
doi: 10.3390/ijms23095248
pubmed: 35563638
pmcid: 9105968
Carpenter SM, Lu LL (2022) Leveraging antibody, B cell and Fc receptor interactions to understand heterogeneous immune responses in tuberculosis. Front Immunol 13:830482. https://doi.org/10.3389/fimmu.2022.830482
doi: 10.3389/fimmu.2022.830482
pubmed: 35371092
pmcid: 8968866
Chakravarty SD, Zhu G, Tsai MC, Mohan VP, Marino S, Kirschner DE et al (2008) Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs. Infect Immun 76(3):916–926. https://doi.org/10.1128/IAI.01011-07
doi: 10.1128/IAI.01011-07
pubmed: 18212087
pmcid: 2258824
Collins FM, Congdon CC, Morrison NE (1975) Growth of mycobacterium bovis (BCG) in T lymphocyte-depleted mice. Infect Immunity 11(1):57–64
doi: 10.1128/iai.11.1.57-64.1975
Cutone A, Rosa L, Lepanto MS, Scotti MJ, Berlutti F, Bonaccorsi di Patti MC et al (2017) Lactoferrin efficiently counteracts the inflammation-induced changes of the iron homeostasis system in macrophages. Front Immunol 8:705. https://doi.org/10.3389/fimmu.2017.00705
doi: 10.3389/fimmu.2017.00705
pubmed: 28663751
pmcid: 5471297
Czajkowsky DM, Hu J, Shao Z, Pleass RJ (2012) Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med 4(10):1015–1028. https://doi.org/10.1002/emmm.201201379
doi: 10.1002/emmm.201201379
pubmed: 22837174
pmcid: 3491832
de Paula RR, Marinho FV, Fahel JS, Oliveira SC (2017) Contribution of intercellular adhesion molecule 1 (ICAM-1) to control Mycobacterium avium infection. Microbes Infect 19(11):527–535. https://doi.org/10.1016/j.micinf.2017.09.005
doi: 10.1016/j.micinf.2017.09.005
pubmed: 28943322
Dorhoi A, Kaufmann SH (2014) Tumor necrosis factor alpha in mycobacterial infection. Semin Immunol 26(3):203–209. https://doi.org/10.1016/j.smim.2014.04.003
doi: 10.1016/j.smim.2014.04.003
pubmed: 24819298
Drago-Serrano ME, Campos-Rodriguez R, Carrero JC, de la Garza M (2017) Lactoferrin: balancing ups and downs of inflammation due to microbial infections. Int J Mol Sci 18(3):501. https://doi.org/10.3390/ijms18030501
doi: 10.3390/ijms18030501
pubmed: 28257033
pmcid: 5372517
Drago-Serrano ME, Campos-Rodriguez R, Carrero JC, de la Garza M (2018) Lactoferrin and peptide-derivatives: antimicrobial agents with potential use in nonspecific immunity modulation. Curr Pharm Des 24(10):1067–1078. https://doi.org/10.2174/1381612824666180327155929
doi: 10.2174/1381612824666180327155929
pubmed: 29589540
Fischer R, Debbabi H, Blais A, Dubarry M, Rautureau M, Boyaka PN et al (2007) Uptake of ingested bovine lactoferrin and its accumulation in adult mouse tissues. Int Immunopharmacol 7(10):1387–1393. https://doi.org/10.1016/j.intimp.2007.05.019
doi: 10.1016/j.intimp.2007.05.019
pubmed: 17673154
Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ et al (1995) Tumor necrosis factor-alpha is required in the protective immune response against mycobacterium tuberculosis in mice. Immunity 2(6):561–572. https://doi.org/10.1016/1074-7613(95)90001-2
doi: 10.1016/1074-7613(95)90001-2
pubmed: 7540941
Furlund CB, Ulleberg EK, Devold TG, Flengsrud R, Jacobsen M, Sekse C et al (2013) Identification of lactoferrin peptides generated by digestion with human gastrointestinal enzymes. J Dairy Sci 96(1):75–88. https://doi.org/10.3168/jds.2012-5946
doi: 10.3168/jds.2012-5946
pubmed: 23141828
Guidry TV, Olsen M, Kil KS, Hunter RL Jr, Geng YJ, Actor JK (2004) Failure of CD1D-/- mice to elicit hypersensitive granulomas to mycobacterial cord factor trehalose 6,6’-dimycolate. J Interferon Cytokine Res 24(6):362–371. https://doi.org/10.1089/107999004323142222
doi: 10.1089/107999004323142222
pubmed: 15212710
Hao W, Schlesinger LS, Friedman A (2016) Modeling granulomas in response to infection in the lung. PLoS ONE 11(3):e0148738. https://doi.org/10.1371/journal.pone.0148738
doi: 10.1371/journal.pone.0148738
pubmed: 26986986
pmcid: 4795641
Hwang S-A, Kruzel ML, Actor JK (2014) Immunomodulatory effects of recombinant lactoferrin during MRSA infection. Int Immunopharmacol 20(1):157–163
doi: 10.1016/j.intimp.2014.02.029
pubmed: 24613206
pmcid: 4017373
Hwang S-A, Kruzel ML, Actor JK (2016a) Oral recombinant human or mouse lactoferrin reduces mycobacterium tuberculosis TDM induced granulomatous lung pathology. Biochem Cell Biol 95(1):148–154
doi: 10.1139/bcb-2016-0061
pubmed: 28165282
pmcid: 6006514
Hwang S-A, Kruzel ML, Actor JK (2016b) Recombinant human lactoferrin modulates human PBMC derived macrophage responses to BCG and LPS. Tuberculosis 101:S53–S62
doi: 10.1016/j.tube.2016.09.011
Hwang S-A, Byerly CD, Actor JK (2019) Mycobacterial trehalose 6, 6′-dimycolate induced vascular occlusion is accompanied by subendothelial inflammation. Tuberculosis (edinb) 116:S118–S122. https://doi.org/10.1016/j.tube.2019.04.019
doi: 10.1016/j.tube.2019.04.019
Hwang SA, Kruzel ML, Actor JK (2017) Oral recombinant human or mouse lactoferrin reduces Mycobacterium tuberculosis TDM induced granulomatous lung pathology. Biochem Cell Biol 95(1):148–154. https://doi.org/10.1139/bcb-2016-0061
doi: 10.1139/bcb-2016-0061
pubmed: 28165282
Ishikawa E, Ishikawa T, Morita YS, Toyonaga K, Yamada H, Takeuchi O et al (2009) Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J Exp Med 206(13):2879–2888
doi: 10.1084/jem.20091750
pubmed: 20008526
pmcid: 2806462
Jafari R, Zolbanin NM, Rafatpanah H, Majidi J, Kazemi T (2017) Fc-fusion proteins in therapy: an updated view. Curr Med Chem 24(12):1228–1237. https://doi.org/10.2174/0929867324666170113112759
doi: 10.2174/0929867324666170113112759
pubmed: 28088904
Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P (1989) The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56(5):731–740. https://doi.org/10.1016/0092-8674(89)90676-4
doi: 10.1016/0092-8674(89)90676-4
pubmed: 2647299
Kitagawa H, Yoshizawa Y, Yokoyama T, Takeuchi T, Talukder MJ, Shimizu H et al (2003) Persorption of bovine lactoferrin from the intestinal lumen into the systemic circulation via the portal vein and the mesenteric lymphatics in growing pigs. J Vet Med Sci 65(5):567–572. https://doi.org/10.1292/jvms.65.567
doi: 10.1292/jvms.65.567
pubmed: 12808207
Kowalczyk P, Kaczynska K, Kleczkowska P, Bukowska-Osko I, Kramkowski K, Sulejczak D (2022) The lactoferrin phenomenon-a miracle molecule. Molecules 27(9):2941. https://doi.org/10.3390/molecules27092941
doi: 10.3390/molecules27092941
pubmed: 35566292
pmcid: 9104648
Kruzel ML, Zimecki M, Actor JK (2017) Lactoferrin in a context of inflammation-induced pathology. Front Immunol 8:1438. https://doi.org/10.3389/fimmu.2017.01438
doi: 10.3389/fimmu.2017.01438
pubmed: 29163511
pmcid: 5681489
Kruzel ML, Actor JK, Boldogh I, Zimecki M (2007) Lactoferrin in health and disease. Postepy Higieny i Medycyny Doswiadczalnej 61:261–267
pubmed: 17507874
Kruzel ML, Hwang S-A, Olszewska P, Actor JK (2019) Systemic effects of oral lactoferrin. In The 14th International Conference on Lactoferrin Structure, Function and Applications, Lima, Peru.
Kruzel ML, Olszewska P, Pazdrak B, Krupinska AM, Actor JK (2021) New insights into the systemic effects of oral lactoferrin: transcriptome profiling. Biochem Cell Biol 99(1):47–53. https://doi.org/10.1139/bcb-2020-0069
doi: 10.1139/bcb-2020-0069
pubmed: 32476452
Kruzel ML, Actor JK, Radak Z, Bacsi A, Saavedra-Molina A, Boldogh I (2010) Lactoferrin decreases LPS-induced mitochondrial dysfunction in cultured cells and in animal endotoxemia model. Innate Immun 16(2):67–79. https://doi.org/10.1177/1753425909105317
doi: 10.1177/1753425909105317
pubmed: 19723832
Kruzel ML, Actor JK, Zimecki M, Wise J, Płoszaj P, Mirza S et al (2013) Novel recombinant human lactoferrin: differential activation of oxidative stress related gene expression. J Biotechnol 168(4):666–675
doi: 10.1016/j.jbiotec.2013.09.011
pubmed: 24070904
pmcid: 3987904
Lang R (2013) Recognition of the mycobacterial cord factor by Mincle: relevance for granuloma formation and resistance to tuberculosis. Front Immunol 4:5. https://doi.org/10.3389/fimmu.2013.00005
doi: 10.3389/fimmu.2013.00005
pubmed: 23355839
pmcid: 3553576
Latorre D, Berlutti F, Valenti P, Gessani S, Puddu P (2012) LF immunomodulatory strategies: mastering bacterial endotoxin. Biochem Cell Biol 90(3):269–278. https://doi.org/10.1139/o11-059
doi: 10.1139/o11-059
pubmed: 22300429
Legrand D (2012) Lactoferrin, a key molecule in immune and inflammatory processes. Biochem Cell Biol 90(3):252–268. https://doi.org/10.1139/o11-056
doi: 10.1139/o11-056
pubmed: 22136726
Legrand D (2016) Overview of lactoferrin as a natural immune modulator. J Pediatr 173(Suppl):S10–S15. https://doi.org/10.1016/j.jpeds.2016.02.071
doi: 10.1016/j.jpeds.2016.02.071
pubmed: 27234406
Lepanto MS, Rosa L, Paesano R, Valenti P, Cutone A (2019) Lactoferrin in aseptic and septic inflammation. Molecules 24(7):1323. https://doi.org/10.3390/molecules24071323
doi: 10.3390/molecules24071323
pubmed: 30987256
pmcid: 6480387
Li HY, Yang HG, Wu HM, Yao QQ, Zhang ZY, Meng QS et al (2021) Inhibitory effects of lactoferrin on pulmonary inflammatory processes induced by lipopolysaccharide by modulating the TLR4-related pathway. J Dairy Sci 104(7):7383–7392. https://doi.org/10.3168/jds.2020-19232
doi: 10.3168/jds.2020-19232
pubmed: 33838887
Lopes RL, Borges TJ, Zanin RF, Bonorino C (2016) IL-10 is required for polarization of macrophages to M2-like phenotype by mycobacterial DnaK (heat shock protein 70). Cytokine 85:123–129. https://doi.org/10.1016/j.cyto.2016.06.018
doi: 10.1016/j.cyto.2016.06.018
pubmed: 27337694
Marakalala MJ, Martinez FO, Pluddemann A, Gordon S (2018) Macrophage heterogeneity in the immunopathogenesis of tuberculosis. Front Microbiol 9:1028. https://doi.org/10.3389/fmicb.2018.01028
doi: 10.3389/fmicb.2018.01028
pubmed: 29875747
pmcid: 5974223
Matsunaga I, Moody DB (2009) Mincle is a long sought receptor for mycobacterial cord factor. J Exp Med 206(13):2865–2868. https://doi.org/10.1084/jem.20092533
doi: 10.1084/jem.20092533
pubmed: 20008525
pmcid: 2806465
Nguyen TKT, Niaz Z, Kruzel ML, Actor JK (2022) Recombinant human lactoferrin reduces inflammation and increases fluoroquinolone penetration to primary granulomas during mycobacterial infection of C57Bl/6 mice. Arch Immunol Ther Exp 70(1):9. https://doi.org/10.1007/s00005-022-00648-7
doi: 10.1007/s00005-022-00648-7
Nguyen TKT, Niaz Z, d’Aigle J, Hwang SA, Kruzel ML, Actor JK (2021) Lactoferrin reduces mycobacterial M1-type inflammation induced with trehalose 6,6’-dimycolate and facilitates the entry of fluoroquinolone into granulomas. Biochem Cell Biol 99(1):73–80. https://doi.org/10.1139/bcb-2020-0057
doi: 10.1139/bcb-2020-0057
pubmed: 32402212
Nguyen TKT, d’Aigle J, Chinea L, Niaz Z, Hunter RL, Hwang SA et al (2020) Mycobacterial trehalose 6,6’-dimycolate-induced M1-type inflammation. Am J Pathol 190(2):286–294. https://doi.org/10.1016/j.ajpath.2019.10.006
doi: 10.1016/j.ajpath.2019.10.006
pubmed: 31734231
pmcid: 7013273
Olson RM, Dhariwala MO, Mitchell WJ, Skyberg JA, Anderson DM (2021) Modification of the pulmonary MyD88 inflammatory response underlies the role of the yersinia pestis pigmentation locus in primary pneumonic plague. Infect Immun. https://doi.org/10.1128/IAI.00595-20
doi: 10.1128/IAI.00595-20
pubmed: 34228495
pmcid: 8445175
Palucci I, Delogu G (2018) Host directed therapies for tuberculosis: future strategies for an ancient disease. Chemotherapy 63(3):172–180. https://doi.org/10.1159/000490478
doi: 10.1159/000490478
pubmed: 30032143
Pelletier M, Forget A, Bourassa D, Gros P, Skamene E (1982) Immunopathology of BCG infection in genetically resistant and susceptible mouse strains. J Immunol 129(5):2179–2185
doi: 10.4049/jimmunol.129.5.2179
pubmed: 6749986
Perez RL, Roman J, Roser S, Little C, Olsen M, Indrigo J et al (2000) Cytokine message and protein expression during lung granuloma formation and resolution induced by the mycobacterial cord factor trehalose-6,6’-dimycolate. J Interferon Cytokine Res 20(9):795–804. https://doi.org/10.1089/10799900050151067
doi: 10.1089/10799900050151067
pubmed: 11032399
Redford PS, Murray PJ, O’Garra A (2011) The role of IL-10 in immune regulation during M. tuberculosis infection. Mucosal Immunol 4(3):261–270. https://doi.org/10.1038/mi.2011.7
doi: 10.1038/mi.2011.7
pubmed: 21451501
Reece ST, Kaufmann SH (2012) Floating between the poles of pathology and protection: can we pin down the granuloma in tuberculosis? Curr Opin Microbiol 15(1):63–70. https://doi.org/10.1016/j.mib.2011.10.006
doi: 10.1016/j.mib.2011.10.006
pubmed: 22074861
Refai A, Gritli S, Barbouche MR, Essafi M (2018) Mycobacterium tuberculosis virulent factor ESAT-6 drives macrophage differentiation toward the pro-inflammatory M1 phenotype and subsequently switches it to the anti-inflammatory M2 phenotype. Front Cell Infect Microbiol 8:327. https://doi.org/10.3389/fcimb.2018.00327
doi: 10.3389/fcimb.2018.00327
pubmed: 30283745
pmcid: 6157333
Rosa L, Cutone A, Lepanto MS, Paesano R, Valenti P (2017) Lactoferrin: a natural glycoprotein involved in iron and inflammatory homeostasis. Int J Mol Sci 18(9):1985. https://doi.org/10.3390/ijms18091985
doi: 10.3390/ijms18091985
pubmed: 28914813
pmcid: 5618634
Russell DG (2007) Who puts the tubercle in tuberculosis? Nat Rev Microbiol 5(1):39–47. https://doi.org/10.1038/nrmicro1538
doi: 10.1038/nrmicro1538
pubmed: 17160001
Russell DG, Cardona PJ, Kim MJ, Allain S, Altare F (2009) Foamy macrophages and the progression of the human tuberculosis granuloma. Nat Immunol 10(9):943–948. https://doi.org/10.1038/ni.1781
doi: 10.1038/ni.1781
pubmed: 19692995
pmcid: 2759071
Saraiva M, O’Garra A (2010) The regulation of IL-10 production by immune cells. Nat Rev Immunol 10(3):170–181. https://doi.org/10.1038/nri2711
doi: 10.1038/nri2711
pubmed: 20154735
Schoenen H, Bodendorfer B, Hitchens K, Manzanero S, Werninghaus K, Nimmerjahn F et al (2010) Cutting edge: mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J Immunol 184(6):2756–2760. https://doi.org/10.4049/jimmunol.0904013
doi: 10.4049/jimmunol.0904013
pubmed: 20164423
Sienkiewicz M, Jaskiewicz A, Tarasiuk A, Fichna J (2021) Lactoferrin: an overview of its main functions, immunomodulatory and antimicrobial role, and clinical significance. Crit Rev Food Sci Nutr. https://doi.org/10.1080/10408398.2021.1895063
doi: 10.1080/10408398.2021.1895063
pubmed: 33685299
Siqueiros-Cendon T, Arevalo-Gallegos S, Iglesias-Figueroa BF, Garcia-Montoya IA, Salazar-Martinez J, Rascon-Cruz Q (2014) Immunomodulatory effects of lactoferrin. Acta Pharmacol Sin 35(5):557–566. https://doi.org/10.1038/aps.2013.200
doi: 10.1038/aps.2013.200
pubmed: 24786230
pmcid: 4814036
Takeuchi T, Jyonotsuka T, Kamemori N, Kawano G, Shimizu H, Ando K et al (2006) Enteric-formulated lactoferrin was more effectively transported into blood circulation from gastrointestinal tract in adult rats. Exp Physiol 91(6):1033–1040. https://doi.org/10.1113/expphysiol.2006.035543
doi: 10.1113/expphysiol.2006.035543
pubmed: 16959821
Tobin DM (2015) Host-directed therapies for tuberculosis. Cold Spring Harbor Perspect Med. https://doi.org/10.1101/cshperspect.a021196
doi: 10.1101/cshperspect.a021196
Tomioka H, Sano C, Tatano Y (2017) Host-directed therapeutics against mycobacterial infections. Curr Pharm Des 23(18):2644–2656. https://doi.org/10.2174/1381612822666161202121550
doi: 10.2174/1381612822666161202121550
pubmed: 27908271
Vogel HJ (2012) Lactoferrin, a bird’s eye view. Biochem Cell Biol 90(3):233–244. https://doi.org/10.1139/o2012-016
doi: 10.1139/o2012-016
pubmed: 22540735
Wang B, Timilsena YP, Blanch E, Adhikari B (2019) Lactoferrin: structure, function, denaturation and digestion. Crit Rev Food Sci Nutr 59(4):580–596. https://doi.org/10.1080/10408398.2017.1381583
doi: 10.1080/10408398.2017.1381583
pubmed: 28933602
Welsh KJ, Hwang S-A, Hunter RL, Kruzel ML, Actor JK (2010) Lactoferrin modulation of mycobacterial cord factor trehalose 6–6’-dimycolate induced granulomatous response. Transl Res 156(4):207–215
doi: 10.1016/j.trsl.2010.06.001
pubmed: 20875896
pmcid: 2948024
Welsh KJ, Hwang S-A, Boyd S, Kruzel ML, Hunter RL, Actor JK (2011) Influence of oral lactoferrin on mycobacterium tuberculosis induced immunopathology. Tuberculosis 91:S105–S113
doi: 10.1016/j.tube.2011.10.019
pubmed: 22138562
Welsh KJ, Abbott AN, Hwang S-A, Indrigo J, Armitige LY, Blackburn MR et al (2008a) A role for tumour necrosis factor-α, complement C5 and interleukin-6 in the initiation and development of the mycobacterial cord factor trehalose 6, 6′-dimycolate induced granulomatous response. Microbiology 154(Pt 6):1813
doi: 10.1099/mic.0.2008/016923-0
pubmed: 18524936
Welsh KJ, Abbott AN, Hwang SA, Indrigo J, Armitige LY, Blackburn MR et al (2008b) A role for tumour necrosis factor-alpha, complement C5 and interleukin-6 in the initiation and development of the mycobacterial cord factor trehalose 6,6’-dimycolate induced granulomatous response. Microbiology 154(Pt 6):1813–1824. https://doi.org/10.1099/mic.0.2008/016923-0
doi: 10.1099/mic.0.2008/016923-0
pubmed: 18524936
Winchell CG, Mishra BB, Phuah JY, Saqib M, Nelson SJ, Maiello P et al (2020) Evaluation of IL-1 blockade as an adjunct to linezolid therapy for tuberculosis in mice and macaques. Front Immunol 11:891. https://doi.org/10.3389/fimmu.2020.00891
doi: 10.3389/fimmu.2020.00891
pubmed: 32477361
pmcid: 7235418
Wright SW, Lovelace-Macon L, Ducken D, Tandhavanant S, Teparrukkul P, Hantrakun V et al (2020) Lactoferrin is a dynamic protein in human melioidosis and is a TLR4-dependent driver of TNF-alpha release in Burkholderia thailandensis infection in vitro. PLoS Negl Trop Dis 14(8):e0008495. https://doi.org/10.1371/journal.pntd.0008495
doi: 10.1371/journal.pntd.0008495
pubmed: 32764765
pmcid: 7439809
Zhao X, Kruzel M, Ting SM, Sun G, Savitz SI, Aronowski J (2021) Optimized lactoferrin as a highly promising treatment for intracerebral hemorrhage: pre-clinical experience. J Cereb Blood Flow Metab 41(1):53–66. https://doi.org/10.1177/0271678X20925667
doi: 10.1177/0271678X20925667
pubmed: 32438861
Zimecki M, Kruzel ML, Hwang SA, Wilk KM, Actor JK (2021) Lactoferrin as an adjuvant for the generation of delayed type hypersensitivity to orally administered antigen. Ann Clin Lab Sci 51(3):359–367
pubmed: 34162566
Zumla A, Rao M, Dodoo E, Maeurer M (2016) Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis. BMC Med 14:89. https://doi.org/10.1186/s12916-016-0635-1
doi: 10.1186/s12916-016-0635-1
pubmed: 27301245
pmcid: 4908783